


HSP70-IN-4

Cat. No.:	HY-18406
CAS No.:	1427450-47-2
Molecular Formula:	C ₂₇ H ₂₇ N ₃ O ₄ S ₃
Molecular Weight:	553.72
Target:	HSP
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HSP70-IN-4 (Compound YM-01) is an Hsp70 inhibitor with an IC ₅₀ of 3.2 μM. HSP70-IN-4 is not BBB permeable ^[1] .								
IC₅₀ & Target	HSP70 3.2 μM (IC ₅₀)								
In Vitro	<p>HSP70-IN-4 (Compound YM-01; 50 μM) significantly enhances the binding of Hsp70 to a misfolded protein^[1].</p> <p>HSP70-IN-4 (0-30 μM; 72 h) inhibits MDA-MB-231, MCF10A and MCF7 viability with EC₅₀s of 2.0 ± 0.2, 3.3 ± 0.3 and 5.2 ± 0.8 μM, respectively^[1].</p> <p>HSP70-IN-4 is stable in water (at least 8 h at room temperature)^[1].</p> <p>HSP70-IN-4 is rapidly metabolized (t_{1/2} value of ~2-4 min) in human liver microsomes^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF7, MCF10A and MDA-MB-231</td> </tr> <tr> <td>Concentration:</td> <td>0-30 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited viability with EC₅₀s of 2.0 ± 0.2, 3.3 ± 0.3 and 5.2 ± 0.8 μM for MDA-MB-231, MCF10A and MCF7, respectively.</td> </tr> </table>	Cell Line:	MCF7, MCF10A and MDA-MB-231	Concentration:	0-30 μM	Incubation Time:	72 h	Result:	Inhibited viability with EC ₅₀ s of 2.0 ± 0.2, 3.3 ± 0.3 and 5.2 ± 0.8 μM for MDA-MB-231, MCF10A and MCF7, respectively.
Cell Line:	MCF7, MCF10A and MDA-MB-231								
Concentration:	0-30 μM								
Incubation Time:	72 h								
Result:	Inhibited viability with EC ₅₀ s of 2.0 ± 0.2, 3.3 ± 0.3 and 5.2 ± 0.8 μM for MDA-MB-231, MCF10A and MCF7, respectively.								
In Vivo	<p>HSP70-IN-4 (Compound YM-01) cannot pass the blood-brain barrier^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>CD1 mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection (Pharmacokinetic Analysis)</td> </tr> <tr> <td>Result:</td> <td>Initial pharmacokinetics of HSP70-IN-4 (Compound YM-01; 20 mg/kg; i.v.)^[1]</td> </tr> </table>	Animal Model:	CD1 mice ^[1]	Dosage:	20 mg/kg	Administration:	Intravenous injection (Pharmacokinetic Analysis)	Result:	Initial pharmacokinetics of HSP70-IN-4 (Compound YM-01; 20 mg/kg; i.v.) ^[1]
Animal Model:	CD1 mice ^[1]								
Dosage:	20 mg/kg								
Administration:	Intravenous injection (Pharmacokinetic Analysis)								
Result:	Initial pharmacokinetics of HSP70-IN-4 (Compound YM-01; 20 mg/kg; i.v.) ^[1]								

hour	plasma (ng/mL)	brain (ng/g)	kidney (ng/g)
0.16	359	0	74378
1	324	0	63231

REFERENCES

[1]. Miyata Y, et al. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem Neurosci. 2013 Jun 19;4(6):930-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA